Sort   by:  
 Page size 
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis (FIA-MS) (C.saccharolyticum;E.coli;L.plantarum;L.lactis;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1791 | MetaboLights
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: secreted metabolite analysis for resting cells (B.uniformis;C.saccharolyticum assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1757 | MetaboLights
ProteomicsSystemwide disassembly and assembly of SCF ubiquitin ligase complexes
Cells adapt to ever-changing environmental cues by remodeling their inventories of multiprotein complexes. The cellular repertoire of modular multiprotein SCF (SKP1-CUL1-Fbox protein) E3 ligase complexes - which mediate much protein degradation - requires CAND1 to distribute the limiting CUL1 subuni...
ORGANISM(S): Homo sapiens (Human) 
2023-04-14 | PXD038661 | Pride
Crl Ligase Cand1 Scf Formation Assembly Ubiquitin Complex E3 
MetabolomicsBioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. Interactions at this level have only recently started to being systematically mapped and the main underlying mechanism proposed is chemical transformation of drugs by microbes (biotransformation). Here, we invest...

2021-07-20 | MTBLS1792 | MetaboLights
ProteomicsCharacterization of proteome changes after 48 hours of TR-57 (ClpP agonist) treatment
ONC201 is a first-in-class, FDA approved small molecule activator of the mitochondrial ATP-dependent caseinolytic peptidase P (ClpP). This and other related small molecules referred to as ClpP agonists, exert antiproliferative effects in several cancer cell types. We report that ONC201 and highly p...
ORGANISM(S): Homo sapiens (Human) 
2026-09-21 | PXD067842 | Pride
Cell cycle arrest Mitochondrial metabolism Regulation of cell death Clpp agonist Dna damage Triple-negative breast cancer Senescence 
UnknownE3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate fidelity.
Not available
S-EPMC10080726 | biostudies-literature
ProteomicsPrinciples of isoform-specific targeted protein degradation engaging the C-degron E3 KLHDC2
Targeted protein degradation (TPD) via molecular glues or PROTACs (Proteolysis-targeting chimeras) is an up-and-coming drug modality holding promise to drug the “undrugabbles.” Further expanding the collection of targetable E3 ligases for TPD, we report the discovery of ligands targeting the C-END d...
ORGANISM(S): Homo sapiens (Human) 
2025-01-18 | PXD051581 | Pride
Protac Tpd Ubiquitin Brd3 Klhdc2 
UnknownPrinciples of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2.
Not available
S-EPMC11470957 | biostudies-literature
GenomicsPromoter proximal pausing and its regulation by c-Myc in embryonic stem cells: ChIP-Seq
Recruitment of the RNA Polymerase II (Pol II) transcription initiation apparatus to promoters by specific DNA binding transcription factors is well recognized as a key regulatory step in gene expression. We describe here evidence that promoter-proximal pausing is a general feature of transcription ...
ORGANISM(S): Mus musculus 
2010-04-02 | E-GEOD-20530 | biostudies-arrayexpress
UnknownA link between FTO, ghrelin, and impaired brain food-cue responsivity.
Not available
S-EPMC3726147 | biostudies-literature
Sort   by:  
 Page size